Accéder au contenu
MilliporeSigma
Toutes les photos(1)

Documents

CBL404

Sigma-Aldrich

Anti-p53 Antibody, aa 211-220, clone240

clone PAb240, Chemicon®, from mouse

Synonyme(s) :

Anti-p53 antibody

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Code UNSPSC :
12352203
eCl@ss :
32160702
Nomenclature NACRES :
NA.41

Source biologique

mouse

Niveau de qualité

Forme d'anticorps

purified antibody

Type de produit anticorps

primary antibodies

Clone

PAb240, monoclonal

Espèces réactives

hamster, monkey, mouse, chicken, human, rat, bovine

Fabricant/nom de marque

Chemicon®

Technique(s)

immunohistochemistry: suitable
immunoprecipitation (IP): suitable
western blot: suitable

Isotype

IgG1

Adéquation

not suitable for immunohistochemistry (Paraffin)

Numéro d'accès NCBI

Numéro d'accès UniProt

Conditions d'expédition

wet ice

Informations sur le gène

human ... TP53(7157)

Description générale

p53 was discovered in 1979 as a cellular protein associating with the transforming protein of SV40 tumor virus. Since then, many different biochemical functions have been attributed to the 53 kD phosphoprotein. Experimental evidence has suggested that p53 acts as a negative regulator of cell growth in normal cells (Finlay, 1989). Thus, the inactivation or mutation of p53 may be an essential step in the development of malignancy (Lane and Benchmol, 1990). Wild-type p53 levels in normal cells and tissues were found to be very low. Mutant p53 polypeptide, however, is often found to be present at high concentrations in mammalian tumors and tumor cell lines. For example, in an immuno-histochemistry study 40% of human breast cancer showed elevated levels of mutant p53 in the cell nucleus. Mutations of the p53 protein have some characteristic features:

a) Most of them are missense point mutations giving rise to an altered protein function.

b) Many -but not all- mutant p53 proteins exhibit a common mutant structure, which can be recognized by monoclonal antibodies specific for p53 in the mutant conformation.

Spécificité

PAb 240 recognizes an epitope of p53 tumor suppressor protein between amino acids 211 and 220 (Gannon, 1990; Legros, 1994) in human, mouse, rat, hamster, monkey, cow and chicken. Assaying native samples (immunoprecipitation, ELISA) the PAb 240 detects only the mutant forms of p53 (Gannon, 1990; Said, 1994). In methods using denatured samples [Western blot analysis (Gannon, 1990) and immunohistochemistry of frozen tissue sections (Said, 1994; Bartek, 1991; Walker, 1991)], the PAb 240 recognizes both mutant and denatured wild-type p53.

Immunogène

Epitope: aa 211-220
Murine p53-beta galactosidase fusion protein expressed in E. coli.

Application

Detect p53 with Anti-p53 Antibody, aa 211-220, clone240 (Mouse Monoclonal Antibody), that has been shown to work in IP, WB & IHC.
Detection of p53 oncogene protein

Detection of mutant p53

Prevalence of detection using CBL 404

-50% colon carcinoma sections positive (30 samples)

-70% lung carcinoma sections positive (50 samples)

-30% carcinoma breast samples positive (50 samples)

Normal and pre-malignant tissues negative

Reacts on methacarn fixed tissue

Optimal working dilutions must be determined by the end user.
Research Category
Epigenetics & Nuclear Function
Research Sub Category
Transcription Factors

Liaison

Replaces: 04-1083

Forme physique

Format: Purified
Purified mouse monoclonal in buffer containing 0.1M Tris-glycine (pH 7.4), 0.15M NaCl, with 0.05% sodium azide. We recommend that each laboratory determine an optimum working titre for use in its particular application.

Stockage et stabilité

For use within 1 month of purchase store at +4°C, for long term storage aliquot antibody into small volumes and store at -20°C.

Informations légales

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Clause de non-responsabilité

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Outil de sélection de produits.

Code de la classe de stockage

12 - Non Combustible Liquids

Classe de danger pour l'eau (WGK)

WGK 1

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable


Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Rajan Gogna et al.
The Journal of biological chemistry, 287(4), 2907-2914 (2011-12-08)
Mutant (Mt) p53 abrogates tumor suppression functions of wild-type (WT) p53 through mutant-specific, gain-of-function effects, and patients bearing Mt p53 are chemoresistant. The dominant negative effect of p53 mutants results from their aggregation propensity which causes co-aggregation of WT p53.
Siddharth Singh et al.
The Journal of biological chemistry, 294(38), 14081-14095 (2019-08-02)
TP53 is the most frequently mutated tumor suppressor gene in many cancers, yet biochemical characterization of several of its reported mutations with probable biological significance have not been accomplished enough. Specifically, missense mutations in TP53 can contribute to tumorigenesis through
Wei Liu et al.
Bioscience reports, 40(2) (2020-01-07)
Parietal cells of the gastric mucosa contain a complex and extensive secretory membrane system that harbors gastric H+, K+-adenosine triphosphatase (ATPase), the enzyme primarily responsible for gastric lumen acidification. Here, we describe the characterization of mice deficient in the H+
Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form.
Gannon, J V, et al.
The Embo Journal, 9, 1595-1602 (1990)
Eric Chekwube Aniogo et al.
Molecules (Basel, Switzerland), 26(23) (2021-12-11)
Multidrug resistance (MDR) has posed a significant threat to cancer treatment and has led to the emergence of a new therapeutic regime of photodynamic therapy (PDT) to curb the menace. The PDT modality employs a photosensitiser (PS), excited at a

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique